Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q1 Revenue $766.2M, vs. FactSet Est of $752.2M

Market Closed – Nasdaq			5-day change	1st Jan Change
55.46 ^USD	+2.59%		+3.08%	-6.68%

Published on 05/04/2026
at 04:35 pm EDT

MT Newswires

04:38pm	BioMarin Pharmaceutical Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Guidance Revised	MT
04:35pm	Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q1 Revenue $766.2M, vs. FactSet Est of $752.2M	MT
04:28pm	(BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Revenue Range $3.83B – $3.93B	MT
04:23pm	(BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Adjusted EPS Range $4.85 – $5.05	MT
04:14pm	Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q1 Adjusted EPS $0.76 per Share, vs. FactSet Est of $0.91	MT
May. 02	Biomarin Pharmaceutical Inc. Presents New Data on the Effect of Long-Term Treatment with VOXZOGO on Arm Span, Bone Health and Growth in Children with Achondroplasia	CI
May. 02	Biomarin presents new data on the effect of long-term treatment with Voxzogo® (vosoritide) on arm span, bone health and growth in children with achondroplasia	RE
Apr. 27	BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says	MT
Apr. 27	BioMarin Pharmaceutical Inc. completed the acquisition of Amicus Therapeutics, Inc. from The Vanguard Group, Inc., Wellington Management Group LLP, BlackRock, Inc., William Blair Investment Management, LLC, and others.	CI
Apr. 27	BioMarin Pharmaceutical Closes $4.8 Billion Acquisition of Amicus Therapeutics	MT
Apr. 27	Morgan Stanley Resumes BioMarin Pharmaceutical at Overweight With $120 Price Target	MT
Apr. 21	BioMarin Pharmaceutical Names Ian Clark as Chair	MT
Apr. 21	Biomarin announces board leadership transition	RE
Apr. 21	BioMarin Pharmaceutical Inc. Announces Retirement of Richard A. Meier as Chair of the Board	CI
Apr. 07	BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition	MT

Duration

Period

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin’s commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.